Anemia, Hemolytic: Clinical Trials

280 trials for Anemia, Hemolytic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

143 completed, 39 recruiting, 33 terminated, 25 active not recruiting. 280 Phase 1, 104 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1280Completed 143, Recruiting 39, Terminated 33, Active not recruiting 25, Not yet recruiting 13, Unknown 13, Withdrawn 13, Enrolling by invitation 1
Phase 2104Completed 39, Recruiting 19, Active not recruiting 16, Terminated 14, Unknown 7, Not yet recruiting 4, Withdrawn 4, Enrolling by invitation 1

Follow Anemia, Hemolytic: new trials by email Literature Review of Anemia, Hemolytic trials Research Report on Anemia, Hemolytic

Trials (filtered) newest first · largest first

All 280 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Buprenorphine for the Management of Pain in Children With Sickle Cell Disease
Buprenorphine Buccal Film [Belbuca] - Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis
Phase 1Not yet recruitingNatasha Archer252027-01-012026-11-04
IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
IASO206 injection - Autoimmune Hemolytic Anemia, Relapsed/Refractory
Phase 1Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China182026-12-152026-11-05
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
Minocycline, Placebo - Sickle Cell Disease, Cognitive Impairment
Phase 1Not yet recruitingUniversity of Cincinnati302026-12-012026-11-03
Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia
YTS109 cell - Autoimmune Hemolytic Anemia
Phase 1Not yet recruitingChina Immunotech (Beijing) Biotechnology Co., Ltd.132026-11-182026-10-22
Feasibility and Acceptability of Amani
Amani - Sickle Cell Disease
Phase 1 / Phase 2Not yet recruitingMassachusetts General Hospital402026-11-012026-08-07
F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
F182112 single-agent - Autoimmune Hemolytic Anemia
Phase 1RecruitingInstitute of Hematology & Blood Diseases Hospital, China122026-10-272026-11-04
To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.
Part1: TUL321, Part1: Placebo, Part2: TUL321 - Paroxysmal Nocturnal Hemoglobinuria, PNH
Phase 1RecruitingZhuhai United Laboratories Co., Ltd.942026-08-262026-09-01
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease
autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452 - Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Phase 1RecruitingDaniel Bauer52026-08-012026-10-21
Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
VAS-101 - Sickle Cell Disease, Hemolytic Anemia
Phase 1RecruitingNational Heart, Lung, and Blood Institute (NHLBI)252026-07-312026-10-21
High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study
Vitamin C - Pyruvate Kinase Deficiency, Glucose 6 Phosphate Dehydrogenase Deficiency
Phase 1Not yet recruitingUniversity of Utah32026-07-152026-05-28
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia
Phase 1 / Phase 2RecruitingNational Heart, Lung, and Blood Institute (NHLBI)902026-07-082026-10-13
HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
HY001N Cell Injection - Autoimmune Hemolytic Anemia (AIHA)
Phase 1RecruitingJuventas Cell Therapy Ltd.92026-07-022026-08-05
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant
Phase 1 / Phase 2RecruitingArkansas Children's Hospital Research Institute242026-06-082026-06-04
STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE
Plerixafor Dose Escalation - Sickle Cell Disease
Phase 1 / Phase 2Not yet recruitingHospital Israelita Albert Einstein122026-06-012026-01-14
CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia
Anti-CD20 monoclonal antibody and the BTK inhibitor - Anti-CD20 Monoclonal Antibody, BTK Inhibitors
Phase 1Not yet recruitingQi deng302026-06-012026-05-22
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
hydroxycarbamide - Sickle Cell Disease, Sickle Cell Anemia in Children
Phase 1 / Phase 2RecruitingChildren's Hospital Medical Center, Cincinnati2502026-05-132026-07-16
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
CMS-D017 Capsule, CMS-D017 Placebo Capsule - Paroxysmal Nocturnal Hemoglobinuria, PNH, Complement-mediated Kidney Disease
Phase 1RecruitingShenzhen Kangzhe Biotechnology Co., Ltd.882026-03-052026-04-08
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
zoledronic acid - Congenital Dyserythropoietic Anemia (CDA)
Phase 1 / Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China22026-02-252026-03-13
Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
DREAM01 drug product, anti-inflammatory therapy - Sickle Cell Disease
Phase 1 / Phase 2RecruitingAssistance Publique - Hôpitaux de Paris152026-02-252026-03-04

Showing 20 of 280. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (182)  ·  beta-Thalassemia (35)  ·  Thalassemia (33)  ·  Hemoglobinuria, Paroxysmal (28)  ·  Anemia, Hemolytic, Autoimmune (24)  ·  Hemoglobinopathies (16)  ·  Anemia (14)  ·  Anemia, Diamond-Blackfan (10)  ·  Hematologic Diseases (10)  ·  Vaso-Occlusive Crises (9)  ·  Anemia, Aplastic (7)  ·  Genetic Diseases, Inborn (7)  ·  Hemoglobin SC Disease (6)  ·  Hypertension, Pulmonary (6)

Broader conditions

Hemic and Lymphatic Diseases (280)  ·  Hematologic Diseases (270)  ·  Anemia (266)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (223)  ·  Anemia, Hemolytic, Congenital (217)  ·  Genetic Diseases, Inborn (215)  ·  Hemoglobinopathies (200)  ·  Bone Marrow Diseases (41)  ·  Immune System Diseases (41)  ·  Pathological Conditions, Signs and Symptoms (39)  ·  Thalassemia (31)  ·  Pathologic Processes (30)  ·  Myelodysplastic Syndromes (28)  ·  Autoimmune Diseases (25)

Interventions

Hydroxyurea (16)  ·  Alemtuzumab (14)  ·  Sirolimus (14)  ·  fludarabine (9)  ·  Cyclophosphamide (7)  ·  plerixafor (7)  ·  voxelotor (6)  ·  Abatacept (5)  ·  Hematopoietic Stem Cell Transplantation (5)  ·  Mycophenolic Acid (5)  ·  fludarabine phosphate (5)  ·  Busulfan (4)  ·  Melphalan (4)  ·  Stem Cell Transplantation (4)  ·  Tacrolimus (4)

Sponsors

National Heart, Lung, and Blood Institute (NHLBI) (18)  ·  Institute of Hematology & Blood Diseases Hospital, China (8)  ·  Pfizer (6)  ·  St. Jude Children's Research Hospital (5)  ·  Children's Hospital Medical Center, Cincinnati (4)  ·  City of Hope Medical Center (4)  ·  Emory University (4)  ·  Global Blood Therapeutics (4)  ·  Novo Nordisk A/S (4)  ·  Wuhan Createrna Science and Technology Co., Ltd (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Bellicum Pharmaceuticals (3)  ·  Bioverativ, a Sanofi company (3)  ·  Chengdu Suncadia Medicine Co., Ltd. (3)  ·  Children's Hospital Los Angeles (3)

Countries

United States (177)  ·  China (39)  ·  United Kingdom (17)  ·  Canada (11)  ·  Italy (11)  ·  France (10)  ·  Australia (8)  ·  Netherlands (6)  ·  Spain (6)  ·  Germany (5)  ·  Lebanon (5)  ·  Nigeria (5)  ·  Thailand (5)  ·  Norway (4)  ·  South Africa (4)

Top investigators

John F Tisdale, M.D. (10)  ·  Carla Washington, PhD (3)  ·  Swee Lay Thein, M.D. (3)  ·  A O Dosunmu, M.D. (2)  ·  Abdullah Kutlar, MD (2)  ·  Courtney D Fitzhugh, M.D. (2)  ·  Courtney F Joseph, M.D. (2)  ·  Diane George, MD (2)

Results publications

PMID 36240296, PMID 42133908, PMID 24916507, PMID 26589907, PMID 34175041, PMID 36860093, PMID 36975201, PMID 37254256, PMID 38866240, PMID 40308078, PMID 40891510, PMID 41871072, PMID 17536019, PMID 17620452, PMID 18439858, PMID 18550886, PMID 19208097, PMID 19840322, PMID 20007560, PMID 20117846, PMID 20644039, PMID 20732454, PMID 20797926, PMID 20936416, PMID 21477202, PMID 21742281, PMID 22875626, PMID 22887019, PMID 23377438, PMID 23416852, PMID 23973010, PMID 24296492, PMID 24988449, PMID 25058217, PMID 25222041, PMID 25701866, PMID 25938131, PMID 26021713, PMID 26275071, PMID 26348869, PMID 26504182, PMID 26719803, PMID 27716293, PMID 27862048, PMID 28096387, PMID 28152086, PMID 28249145, PMID 28331623, PMID 28880867, PMID 28884840

NIH funding

2014 (5), 2023 (4), 2019 (3), 1RC2HL101367-01 (1), 1ZIAHL006149-01 (1), 2016 (1), 2017 (1), 2025 (1), K23HL133446 (1), K23HL146904 (1), K24AT009893 (1), P01CA015396 (1), P20GM109021 (1), P30CA033572 (1), R01DK055463 (1)